Home › Companies › CLYM

Climb Bio

Market cap $574M 58.7M shares (10-Q, Oct 30, 2026) × $9.78 close Nov 17, 2026

Most recent annual filing: 2026-03-05

Pipeline (8 active programs)

Capital (as filed)

Cash
$39.7M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$166M Sep 30, 2026
Long-term investments
$22.2M Sep 30, 2026
Operating cash flow
−$12.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$228M cash, runway 2H 2028 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Offering documents (4)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on Climb Bio, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Climb Bio (CLYM) - Scientific Deep Dive for Budoprutug and Pipeline Products Intriguing antibody engineering with early biological validation, but a leaky patent moat, active IP litigation, and late-to-market position make this a clinical data trade rather than a buy-and-hold investment.
  2. Speculative buy speculative UPDATE: Climb Bio (CLYM) - The Smart Money Doubles Down A $110M at-market PIPE led by RA Capital and a roster of healthcare specialists provides a meaningful Bayesian update on the molecule's prospects, and the dilution gap is now paved over, justifying a small speculative position sized for catalyst-trader profiles.
  3. Buy core UPDATE: Climb Bio (CLYM) - The SC Wedge Lands SC bioavailability proven at dose-matched comparison (~80% B-cell depletion matching IV), the catalyst clock compressed to a June ITP readout six weeks out, and management framing grew more confident, justifying an upgrade to Accumulate.
  4. Buy core UPDATE: Climb Bio (CLYM) - The Sweeper Clears Its First Bar CLYM116 cleared safety through 320 mg in 49 healthy volunteers with zero SAEs/DLTs, removing the most binary failure mode for the novel mechanism, while the PK/PD proof slipped to late summer; the Accumulate stance is maintained.
  5. Buy core UPDATE: Climb Bio (CLYM) - The ITP Bar Clears Budoprutug delivered >90% B-cell depletion and +111K platelet rise at 24 weeks in refractory ITP with 3-of-4 rituximab failures responding, providing independent clinical validation of the CD19-over-CD20 thesis and reducing the 'n=5 pMN noise' risk.
  6. Buy core UPDATE: Climb Bio (CLYM) - The Sweeper Gets a Date CLYM116 PK/PD reveal pinned to September 3, Mabworks deal deepened at unchanged economics, and the catalyst cluster compressed into a four-month window; the Accumulate stance is maintained with the caveat that the $100M ATM is a yellow flag worth watching.
  7. Buy core UPDATE: Climb Bio (CLYM) - The Sweeper Delivers Its Number CLYM116 posted a ~29-day half-life (~3x sibeprenlimab) with >90% free APRIL suppression and 60-75% IgA knockdown off a single 320 mg dose, converting the dosing-frequency wedge from modeled to measured; PrisMN replication remains the Q4 lead-asset catalyst.
  8. Hold UPDATE: Climb Bio (CLYM) - The Leaky Sieve The 200 mg PrisMN cohort produced only 74% B-cell depletion versus the 100% Phase 1b headline, complete remission data moved to 2027, and proteinuric patients clear the drug 2x faster, deferring the lead-asset valuation leg while obinutuzumab nears approval.
  9. Hold UPDATE: Climb Bio (CLYM) - Lupus Signal, ATM Tapped SLE data adds breadth with a dose-response signal but does not answer the undefined pMN dose question; the ATM has moved from theory to practice with $10.1M sold at $10, and obinutuzumab's FDA decision is imminent, keeping the stance at Hold pending higher-dose pMN data and the Delaware ruling.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (4 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (43)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)